Healthcare services group Uniphar said it achieved double-digit adjusted earnings per share growth in the first half of 2025, ahead of its expectations, driven by a strong trading performance.
In a trading update for the six months to the end of June, Uniphar said that M&A continues to play an important role in Uniphar's growth strategy, adding that it is maintaining a disciplined approach to capital allocation.
It added that it enters the second half of this year with strong trading momentum, but said that declining interest rates favourably impacting finance costs will be a tailwind to current year EPS expectations.
Uniphar owns pharmacy chains including Allcare and Hickeys.
Ger Rabbette, Uniphar's group chief executive, said that Uniphar has had a strong first half, achieving significant organic gross profit growth.
"We expect to continue this progress into the second half and meet our growth objectives for each of our three divisions for the full year. We remain confident of reaching our €200m EBITDA target by 2028, with at least 80% of our growth being organic," he added.
Breaking down its divisions, the company said its Uniphar Pharma unit delivered double-digit organic gross profit growth during the six month period and remains on track to deliver double-digit organic gross profit growth for the full year.
It said its Uniphar Medtech division reported high single-digit organic gross profit growth during the half and expectations of high single-digit organic gross profit growth for the full year remain unchanged.
And its Supply Chain & Retail division delivered low single-digit organic gross profit growth during the half and remains on track to deliver low single-digit organic gross profit growth for the full year.
